Page 188 - 2021_09-Haematologica-web

J. Venugopal et al.
References
1. Fitzhugh CD, Lauder N, Jonassaint JC, et al. Cardiopulmonary complications leading to premature deaths in adult patients with sickle cell disease. Am J Hematol. 2010; 85(1):36-40.
2. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91(1):288-294.
3. Strouse JJ, Lanzkron S, Urrutia V. The epi- demiology, evaluation and treatment of stroke in adults with sickle cell disease. Expert Rev Hematol. 2011;4(6):597-606.
4. Webb J, Kwiatkowski JL. Stroke in patients with sickle cell disease. Expert Rev Hematol. 2013;6(3):301-316.
5.Sumoza A, de Bisotti R, Sumoza D, Fairbanks V. Hydroxyurea (HU) for preven- tion of recurrent stroke in sickle cell anemia (SCA). Am J Hematol. 2002;71(3):161-165.
6. Ware RE, Mueller BU. The second century of sickle cell disease. Pediatr Blood Cancer. 2012;59(2):352.
7. Hasson C, Veling L, Rico J, Mhaskar R. The role of hydroxyurea to prevent silent stroke in sickle cell disease: systematic review and meta-analysis. Medicine (Baltimore). 2019;98(51):e18225.
8. Teixeira RS, Terse-Ramos R, Ferreira TA, et al. Associations between endothelial dys- function and clinical and laboratory param- eters in children and adolescents with sick- le cell anemia. PLoS One. 2017;12(9): e0184076.
9. Zhou Z, Yee DL, Guchhait P. Molecular link between intravascular hemolysis and vas- cular occlusion in sickle cell disease. Curr Vasc Pharmacol. 2012;10(6):756-761.
10. Conran N, Belcher JD. Inflammation in sickle cell disease. Clin Hemorheol Microcirc. 2018;68(2-3):263-299.
11. Kaul DK, Finnegan E, Barabino GA. Sickle red cell-endothelium interactions. Microcirculation. 2009;16(1):97-111.
12. Vilas-Boas W, Cerqueira BA, Zanette AM, Reis MG, Barral-Netto M, Goncalves MS. Arginase levels and their association with Th17-related cytokines, soluble adhesion molecules (sICAM-1 and sVCAM-1) and hemolysis markers among steady-state sickle cell anemia patients. Ann Hematol. 2010;89(9):877-882.
13. Zennadi R, Chien A, Xu K, Batchvarova M, Telen MJ. Sickle red cells induce adhesion of lymphocytes and monocytes to endotheli- um. Blood. 2008;112(8):3474-3483.
14. Pitanga TN, Oliveira RR, Zanette DL, et al. Sickle red cells as danger signals on proin- flammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell. Cytokine. 2016;83:75-84.
15. Platt OS. Hydroxyurea for the treatment of sickle cell anemia. N Engl J Med. 2008; 358(13):1362-1369.
16. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol. 2010; 85(6):403-408.
17.Dutra FF, Alves LS, Rodrigues D, et al. Hemolysis-induced lethality involves inflammasome activation by heme. Proc Natl Acad Sci U S A. 2014;111(39):E4110- E4118.
18. Wun T, Cordoba M, Rangaswami A, Cheung AW, Paglieroni T. Activated mono- cytes and platelet-monocyte aggregates in
patients with sickle cell disease. Clin Lab
Haematol. 2002;24(2):81-88.
19.Singhal R, Chawla S, Rathore DK, et al.
Development of pro-inflammatory pheno- type in monocytes after engulfing Hb-acti- vated platelets in hemolytic disorders. Clin Immunol. 2017;175:133-142.
20. Kalliolias GD, Ivashkiv LB. Targeting cytokines in inflammatory diseases: focus on interleukin-1-mediated autoinflamma- tion. F1000 Biol Rep. 2009;1:70.
21. Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking inter- leukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov. 2012;11(8):633-652.
22. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-1131.
23.Huang CM, Tsai FJ, Wu JY, Wu MC. Interleukin-1beta and interleukin-1 recep- tor antagonist gene polymorphisms in rheumatoid arthritis. Scand J Rheumatol. 2001;30(4):225-228.
24. Vicari P, Adegoke SA, Mazzotti DR, Cancado RD, Nogutti MA, Figueiredo MS. Interleukin-1beta and interleukin-6 gene polymorphisms are associated with mani- festations of sickle cell anemia. Blood Cells Mol Dis. 2015;54(3):244-249.
25.Denes A, Pinteaux E, Rothwell NJ, Allan SM. Interleukin-1 and stroke: biomarker, harbinger of damage, and therapeutic tar- get. Cerebrovasc Dis. 2011;32(6):517-527.
26. Sobowale OA, Parry-Jones AR, Smith CJ, Tyrrell PJ, Rothwell NJ, Allan SM. Interleukin-1 in stroke: from bench to bed- side. Stroke. 2016;47(8):2160-2167.
27. McCann SK, Cramond F, Macleod MR, Sena ES. Systematic review and meta- analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke: an update. Transl Stroke Res. 2016; 7(5):395-406.
28. Parker LC, Luheshi GN, Rothwell NJ, Pinteaux E. IL-1 beta signalling in glial cells in wildtype and IL-1RI deficient mice. Br J Pharmacol. 2002;136(2):312-320.
29. Thornton P, Pinteaux E, Allan SM, Rothwell NJ. Matrix metalloproteinase-9 and uroki- nase plasminogen activator mediate inter- leukin-1-induced neurotoxicity. Mol Cell Neurosci. 2008;37(1):135-142.
30. Giles JA, Greenhalgh AD, Denes A, et al. Interleukin-1 and platelets as key drivers of cerebrovascular inflammation. Immunology. 2011;135:154.
31.Ching S, Zhang H, Belevych N, et al. Endothelial-specific knockdown of inter- leukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J Neurosci. 2007;27(39):10476-10486.
32. Bolton SJ, Anthony DC, Perry VH. Loss of the tight junction proteins occludin and zonula occludens-1 from cerebral vascular endothelium during neutrophil-induced blood-brain barrier breakdown in vivo. Neuroscience. 1998;86(4):1245-1257.
33. Basu A, Krady JK, Levison SW. Interleukin- 1: a master regulator of neuroinflammation. J Neurosci Res. 2004;78(2):151-156.
34. Allen C, Thornton P, Denes A, et al. Neutrophil cerebrovascular transmigration triggers rapid neurotoxicity through release of proteases associated with decondensed DNA. J Immunol. 2012;189(1):381-392.
35. Li Y, Zhu ZY, Huang TT, et al. The periph- eral immune response after stroke-A dou- ble edge sword for blood-brain barrier integrity. CNS Neurosci Ther. 2018; 24(12):
1115-1128.
36. Fahey E, Doyle SL. IL-1 Family cytokine
regulation of vascular permeability and angiogenesis. Front Immunol. 2019; 10:1426.
37. Paszty C, Brion CM, Manci E, et al. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science. 1997;278(5339):876-878.
38. Ryan TM, Ciavatta DJ, Townes TM. Knockout-transgenic mouse model of sick- le cell disease. Science. 1997;278(5339):873- 876.
39.Wu LC, Sun CW, Ryan TM, Pawlik KM, Ren J, Townes TM. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Blood. 2006; 108(4):1183-1188.
40. Russo HM, Wickenheiser KJ, Luo W, et al. P-selectin glycoprotein ligand-1 regulates adhesive properties of the endothelium and leukocyte trafficking into adipose tissue. Circ Res. 2010;107(3):388-397.
41. Wang J, Tran J, Wang H, et al. mTOR Inhibition improves anaemia and reduces organ damage in a murine model of sickle cell disease. Br J Haematol. 2016; 174(3):461-469.
42. Luo W, Su EJ, Wang J, et al. Increased stroke size following MCA occlusion in a mouse model of sickle cell disease. Blood. 2014; 123(12):1965-1967.
43. Campbell AD, Cui S, Shi L, et al. Forced TR2/TR4 expression in sickle cell disease mice confers enhanced fetal hemoglobin synthesis and alleviated disease pheno- types. Proc Natl Acad Sci U S A. 2011; 108(46):18808-18813.
44. Ching S, He L, Lai W, Quan N. IL-1 type I receptor plays a key role in mediating the recruitment of leukocytes into the central nervous system. Brain Behav Immun. 2005;19(2):127-137.
45. Akassoglou K, Strickland S. Nervous sys- tem pathology: the fibrin perspective. Biol Chem. 2002;383(1):37-45.
46. Adams RA, Passino M, Sachs BD, Nuriel T, Akassoglou K. Fibrin mechanisms and functions in nervous system pathology. Mol Interv. 2004;4(3):163-176.
47. Petersen MA, Ryu JK, Akassoglou K. Fibrinogen in neurological diseases: mecha- nisms, imaging and therapeutics. Nat Rev Neurosci. 2018;19(5):283-301.
48. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997; 337(11):762-769.
49. Steinberg MH. Predicting clinical severity in sickle cell anaemia. Br J Haematol. 2005; 129(4):465-481.
50. Steinberg MH, Rodgers GP. Pathophysiology of sickle cell disease: role of cellular and genetic modifiers. Semin Hematol. 2001;38(4):299-306.
51. Su EJ, Geyer M, Wahl M, et al. The throm- bomodulin analog Solulin promotes reper- fusion and reduces infarct volume in a thrombotic stroke model. J Thromb Haemost. 2011;9(6):1174-1182.
52. Telen MJ. Role of adhesion molecules and vascular endothelium in the pathogenesis of sickle cell disease. Hematology Am Soc Hematol Educ Program. 2007:84-90.
53.Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the prevention of pain crises in sickle cell disease. N Engl J Med. 2017;376(5):429-439.
54. Luo W, Campbell A, Wang H, et al. P- selectin glycoprotein ligand-1 inhibition blocks increased leukocyte-endothelial interactions associated with sickle cell dis-
2476
haematologica | 2021; 106(9)